Experimental immune therapy tested for Tough-to-Treat lung cancer
NCT ID NCT07246304
Summary
This early-stage study is testing a new CAR-T cell therapy called TC-D101 for people with advanced small cell lung cancer that has returned or stopped responding to standard treatments. The study will enroll 24 patients to determine the safest dose and see if the therapy shows early signs of effectiveness. Researchers will collect patients' own immune cells, modify them to target cancer cells, and then infuse them back into the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Jinling Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.